替罗非班在非ST段抬高型心肌梗死患者介入术中应用的有效性研究

Efficacy of tirofiban in percutaneous coronary intervention for NSTEMI

目的研究非ST段抬高型心肌梗死(NSTEMI)患者经皮冠状动脉介入术(PCI)中应用替罗非班的有效性。方法将145例行PCI的非ST段抬高心肌梗死患者随机分为A组(受试组,73例)和B组(对照组,72例)。A组PCI术前给予替罗非班+术中给予推注普通肝素70 U/kg,B组术中推注普通肝素100 U/kg。比较两组射血分数和不良心血管事件:再发胸痛(包括心绞痛、心肌梗死)。结果术前两组患者在年龄、性别构成、危险因素、心功能分级、血管病变指数等临床特点方面差异均无统计学意义(P>0.05),具有可比性。住院及随访期间再发胸痛:A组2例,B组8例。两组复合心血管事件发生率比较差异有统计学意义(P<0.05)。A组、B组的射血分数分别为47.0%±6.4%、56.2%±5.1%,两组比较差异有统计学意义(P<0.05)。结论 NSTEMI患者介入术中使用替罗非班疗效显著。

Objective To investigate the efficacy of tirofiban for patients with NSTEMI undergoing percutaneous coronary interventional therapy （PCI）. Methods 145 patients with NSTEMI were randomized into group A （n = 73 ） and group B （ n = 72）. Group A was given tirofiban before PCI and then normal heparin 70 U/kg iv during operation,group B was given heparin 100 U/kg iv during operation. Ejection fraction and the main adverse cardiac events （MACE）-recurrence of chest pain（ including angina pectoris and myocardial infarction）were recorded and analyzed. Results Clinical characteristics （including age, sex,risk factors, et al）of the two groups were comparable. During the in-hospital and follow-up visits period ：there were 2 and 8 cases of recurrent chest pain in group A and group B. The ejection fraction of group A and group B were 47.0% ＋ 6.4% and 56. 2% -＋ 5. 1%. There were significant differences between the two groups in terms of MACE （ P 〈 0.05 ） and the ejection fraction （ P 〈 0. 05 ）. Conclusion Tirofiban has significant effects on NSTEMI patients during operation.